Lakefront Biotherapeutics has strung together three straight earnings beats and carries a wide stated margin of safety, but revenue is collapsing and margins are deeply compressed, the stock remains in a confirmed downtrend despite a recovering setup, and it has already reached its price target amid a leadership-change flag with a sharply negative stated risk/reward.
Thesis pillars
- Revenue Collapse Margin Compression↑Improving
- Wide Margin Of Safety Valuation→Stable
- Recent Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026· older than 90 days
Lakefront Biotherapeutics (LKFT) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $32.02, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 85).
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus... Read more
Hold if already holding. Not a fresh buy at $32.02, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 85). Chart setup: Death cross but MACD improving, RSI 85. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
No fresh coverage since Oct 14, 2026
Recent Developments — Lakefront Biotherapeutics
Latest news
- NEWS Lakefront Biotherapeutics Completes Sale Of Early-Stage Cell Therapy Pipeline To Armed Cell Therapeutics For €8M Upfront — benzinga Oct 14, 2026 neutral
- NEWS Bank Of America Crosses Below Threshold Of 10% Of Lakefront's Voting Rights, Transparency Notification Shows — benzinga Oct 8, 2026 neutral
- NEWS This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday — benzinga Sep 25, 2026 positive
- NEWS Crude Oil Gains 1%; Cintas Earnings Top Views — benzinga Sep 23, 2026 neutral
- NEWS TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday — benzinga Sep 23, 2026 positive
Latest item Oct 14, 2026 · Generated 2026-11-03T11:44:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $32.02, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 85). Chart setup: Death cross but MACD improving, RSI 85. Maintain position. Not compelling to add more. Analyst target $25.86 reached (−19.2%), stop $30.62 (−4.6%), A.R:R -1.8:1. Score 5.8/10, moderate confidence.
Analyst target $25.86 reached (−19.2% from $32.02); no take-profit level is published. Analyst target $25.86 reached (−19.2%), stop $30.62 (−4.6%), A.R:R -1.8:1. Stop-loss: $30.62.
Analyst target reached - limited upside remaining; Overbought (RSI 85); Value-trap signals (2/5): Revenue declining (-81.5% YoY), Margin compression (op margin -359.3%).
Lakefront Biotherapeutics trades at a P/E of 3.0 (forward -26.9). TrendMatrix value score: 5.6/10. Verdict: Hold.
15 analysts rate LKFT, with a consensus score of 2.5/5. 3 analysts publish price targets averaging $30.
What does Lakefront Biotherapeutics do?Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily...
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.